Sentences with phrase «myeloma trials»

About one - half (45 %) of patients were enrolled in lymphoma trials, one - quarter (24 %) in chronic myeloid leukemia (CML) trials or multiple myeloma trials (22 %), and 2 % of patients were enrolled in trials of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Merck multiple myeloma trials on hold after patient deaths.

Not exact matches

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.

The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.

Clinical trials that specifically test ADAR1 - targeted therapeutics for their safety and efficacy against multiple myeloma are still necessary before this approach could become available to patients.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percent.

All of the patients in the three trials had myeloma that had either relapsed or become resistant to other therapies.

A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own.

«For patients diagnosed with MGUS, maintaining a healthy weight may be a way to prevent the progression to multiple myeloma, if further confirmed by clinical trials.»

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

Trial # 3: Combined autophagy and proteasome inhibition: A phase 1 trial of HCQ and bortezomib in patients with relapsed / refractory myTrial # 3: Combined autophagy and proteasome inhibition: A phase 1 trial of HCQ and bortezomib in patients with relapsed / refractory mytrial of HCQ and bortezomib in patients with relapsed / refractory myeloma

The 2 - year trial will treat 18 people with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments at three sites that are members of the Parker Institute — UPenn; the University of California, San Francisco; and the University of Texas MD Anderson Cancer Center in Houston.

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

The method also is being evaluated in a clinical trial involving patients with multiple myeloma.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma.

«This study presents a novel strategy for treating multiple myeloma, and we hope to bring it to patients as part of a phase I clinical trial as soon as possible,» Hofmeister says.

The trials covered eight cancers: breast, lung, colon, ovarian, prostate, multiple myeloma, lymphoma, and leukemia.

Several of the compounds are currently in clinical trials to treat cancers like leukemia and myeloma.

We have one of the most comprehensive CAR T cell programs in the world, with 14 CAR T clinical trials ongoing and plans to open numerous additional trials in the coming year, including for patients with multiple myeloma, prostate cancer, liver cancer and breast cancer.

But in 1995, after successful clinical trials, the FDA approved the nanodrug Doxil for treating AIDS - related Kaposi sarcoma; later, the agency extended its approved use to ovarian cancer and multiple myeloma, and in Europe doctors use it to fight breast cancer.

Dr. Goodman is also one of the lead contributors to the Intergroup trial of stem cell transplantation and multiple myeloma.

Compared with the United States cancer populations, trials of lymphoma, CLL, CML, and myeloma enrolled a disproportionately higher percentage of patients younger than 65 years.

This page features information on multiple myeloma and immunotherapy clinical trials for multiple myeloma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to people with multiple myeloma.

The researchers noted that initial clinical trial data have been validated in larger phase II trials in the setting of relapsed / refractory HL, non-Hodgkin's lymphoma (NHL), and multiple myeloma (MM).

In myeloma and CLL trials, the proportion of people aged 65 to 74 was higher than the reported incidence.

These patients were significantly underrepresented in trials of new treatments for lymphoma, CLL, and myeloma compared with the incidence of these diseases in that age group.

Another modified peptide POL6326 is in phase II clinical trial in hematopoietic stem cell mobilization in multiple myeloma [128].

ARRY - 520, a novel selective kinesin spindle protein (KSP) inhibitor showed promising clinical activity both alone and combined with low - dose dexamethasone in a phase II clinical trial in patients with relapsed and refractory multiple myeloma.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

«We explored the relationship between response to initial treatment and survival in patients with newly diagnosed multiple myeloma, based on data from 63 randomized clinical trials,» wrote researcher Maria Mainou, of the clinical research and evidence - based medicine unit at Aristotle University of Thessaloniki, Greece, and colleagues.

No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dMyeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dmyeloma in populations of patients who received stem cell transplant and those who did not.

The KEYNOTE - 183, KEYNOTE - 185, and KEYNOTE - 023 trials evaluating the programmed death 1 (PD - 1) inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma were placed on hold due to the increase in deaths on the pembrolizumab arms of KEYNOTE - 183 and KEYNOTE - 185 trials.

In addition, a growing number of immunotherapy clinical trials are in place to test this groundbreaking approach on other cancers like lymphoma, multiple myeloma, and for solid tumors, through trials in glioblastoma, mesothelioma, and ovarian and pancreatic cancer.

Instead, newer trials have suggested that the use of minimal residual disease (MRD) status may be a valid surrogate outcomes for survival in patients with myeloma who achieved CR.

Clinical trials in GVHD, new drugs in leukemia, lymphoma and myeloma.

He was the founding Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core and now chairs the Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB).

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed / refractory myeloma.

High Response Rate Among Lymphoma Patients and Promising Early Results in Trials for Pancreatic Cancer and Multiple Myeloma

Avigan and his colleagues have secured funding to perform a larger clinical trial for their leukemia vaccine, and also are conducting a trial for a vaccine against multiple myeloma, another blood cancer.

Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation?